Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.

MLA

Phillips, Elizabeth J., et al. “Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.” Clinical Pharmacology and Therapeutics, vol. 103, no. 4, Apr. 2018, pp. 574–81. EBSCOhost, https://doi.org/10.1002/cpt.1004.

APA

Phillips, E. J., Sukasem, C., Whirl-Carrillo, M., Müller, D. J., Dunnenberger, H. M., Chantratita, W., Goldspiel, B., Chen, Y.-T., Carleton, B. C., George, A. L., Jr, Mushiroda, T., Klein, T., Gammal, R. S., & Pirmohamed, M. (2018). Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clinical Pharmacology and Therapeutics, 103(4), 574–581. https://doi.org/10.1002/cpt.1004

Chicago

Phillips, Elizabeth J, Chonlaphat Sukasem, Michelle Whirl-Carrillo, Daniel J Müller, Henry M Dunnenberger, Wasun Chantratita, Barry Goldspiel, et al. 2018. “Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.” Clinical Pharmacology and Therapeutics 103 (4): 574–81. doi:10.1002/cpt.1004.